Charles Adler, MD, PhD

• Enfermedad de Parkinson
• Biomarker

Charles H. Adler, MD, PhD has specialized in the diagnosis and treatment of Parkinson’s disease, and performed multiple research studies of patients with Parkinson’s disease, Alzheimer’s disease, and dementia with Lewy bodies for the past 30 years. I serve as Co-PI and Clinical Core Director on a multi-institutional study, the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) program. I am responsible for overseeing clinical assessments and then establishing the final movement disorder and clinicopathologic diagnoses for all subjects that come to autopsy. Additionally, I have a served as PI of multiple clinical trials of PD including multiple biopsy studies assessing for alpha-synuclein in peripheral tissues of PD patients and controls. I have also served as site PI for the DIAGNOSE CTE study assessing biomarkers for CTE in former football players and am on the study consensus diagnostic conference subteam, the clinico-pathological correlations subteam, and the neurological, motor, and headache subteam. I served as site PI for the Parkinson Progression Marker Initiative (PPMI), an international multi-center study investigating biomarkers for Parkinson’s disease.